Timing is everything
for their everything

Rapid fFN® testing can help rule out imminent preterm birth and deliver peace of mind.

Be Confident in Your Care Decisions

Fetal fibronectin (fFN) testing can help reduce unnecessary admissions and interventions, such as steroids. Studies over the last two decades have shown that implementing a standard preterm labor protocol that includes fFN testing may help improve outcomes and optimize resources.1, 2

LEARN MORE ABOUT fFN TESTING
INTERPRET TEST RESULTS

fFN customer testimonials

fFN testing fundamentals

fFN ≠ ROM testing.
Different tests. Different purposes.

Collecting an fFN specimen

Creating a PTL protocol to improve outcomes

Free educational resources & materials

Start with the test that has very high negative predictive value to rule out preterm birth

Determining which patients are in true preterm labor is a challenge.
fFN testing can help rule out ~80% of cases in question.3

Negative Person Icon
Negative Person Icon
Negative Person Icon
Negative Person Icon
Positive Person Icon
Doctor Icon

Multiple studies have shown that clinical assessment and cervical length may not be sufficient to rule out imminent preterm birth in patients. Adding fFN testing to clinical assessment and cervical length can improve preterm birth prediction by as much as 50%.4

WHY TEST FOR FFN?

Intervene when it’s needed—
Ensure peace of mind when it’s not

Fetal fibronectin (fFN) acts as an adhesive glycoprotein at the maternal-fetal interface3 and is usually not detectable in vaginal secretions between 16-35 weeks.5 Its premature presence in vaginal secretions is a biochemical indicator of preterm birth risk. fFN is the single common biochemical marker for all four mechanisms of preterm birth: activation of the maternal/fetal hypothalamic-pituitary-adrenal (HPA) axis, inflammation, decidual hemorrhage and pathological uterine distention.6

Positive Test Icon

When fFN is detectable in the vagina during weeks 22 to 35 of gestation, the Rapid fFN test returns a positive result. This indicates some type of disruption, and that the patient may be at risk of preterm delivery.3

Negative Test Icon

When fFN is not detectable in vaginal secretions, the Rapid fFN test returns a negative result. This indicates that the patient will have a less than 1% chance of delivering in the next two weeks.3

INTERPRET TEST RESULTS

Intervene when it’s needed—
Ensure peace of mind when it’s not

Fetal fibronectin (fFN) acts as an adhesive glycoprotein at the maternal-fetal interface3 and is usually not detectable in vaginal secretions between 16-35 weeks.5 Its premature presence in vaginal secretions is a biochemical indicator of preterm birth risk. fFN is the single common biochemical marker for all four mechanisms of preterm birth: activation of the maternal/fetal hypothalamic-pituitary-adrenal (HPA) axis, inflammation, decidual hemorrhage and pathological uterine distention.6

Positive Test Icon

When fFN is detectable in the vagina during weeks 22 to 35 of gestation, the Rapid fFN test returns a positive result. This indicates some type of disruption, and that the patient may be at risk of preterm delivery.3

Negative Test Icon

When fFN is not detectable in vaginal secretions, the Rapid fFN test returns a negative result. This indicates that the patient will have a less than 1% chance of delivering in the next two weeks.3

INTERPRET TEST RESULTS

Assess preterm birth risk with the Rapid fFN test

Contact us for more information about Rapid fFN®.

CONTACT US

Assess preterm birth risk with the Rapid fFN test

Contact us for more information about Rapid fFN® test.

CONTACT US

References

1. Rose CH, McWeeney DT, Brost BC, et al. Cost-e!ective standardization of preterm labor evaluation. Am J Obstet Gynecol 2010;203:250.e1-5. doi.org/10.1016/j.ajog.2010.06.037 2. Iyer S, McElrath T, Jarolim P, et al, The association of fFN testing on hospital admissions for preterm labor. Open J Obstet Gyn. 2013;3(1):126-129. doi:10.4236/ojog.2013.31024 3. Rapid fFN for the TLiIQ System [package insert]. AW-24196-001, Rev. 001, San Diego, CA: Hologic, Inc.; 2020 4. Gomez R, et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol. 2005; 192(2): 350-359. 5. Goldenberg, RL et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health 1998 Feb; 88(2): 233-8. 6. Lockwood CJ and Kuczynski E. Risk stratification and pathological mechanisms in preterm delivery. Paediatr Perinat Epidemiol. 2001;15(suppl 2):78-89.